390 related articles for article (PubMed ID: 32043788)
1. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Da Vià MC; Solimando AG; Garitano-Trojaola A; Barrio S; Munawar U; Strifler S; Haertle L; Rhodes N; Teufel E; Vogt C; Lapa C; Beilhack A; Rasche L; Einsele H; Kortüm KM
Oncologist; 2020 Feb; 25(2):112-118. PubMed ID: 32043788
[TBL] [Abstract][Full Text] [Related]
2. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
Ernst T; Aebi S; Zander A; Zander T
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
5.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
6. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in
Waldschmidt JM; Kloeber JA; Anand P; Frede J; Kokkalis A; Dimitrova V; Potdar S; Nair MS; Vijaykumar T; Im NG; Guillaumet-Adkins A; Chopra N; Stuart H; Budano L; Sotudeh N; Guo G; Grassberger C; Yee AJ; Laubach JP; Richardson PG; Anderson KC; Raje NS; Knoechel B; Lohr JG
Clin Cancer Res; 2021 Dec; 27(23):6432-6444. PubMed ID: 34518309
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Giesen N; Chatterjee M; Scheid C; Poos AM; Besemer B; Miah K; Benner A; Becker N; Moehler T; Metzler I; Khandanpour C; Seidel-Glaetzer A; Trautmann-Grill K; Kortüm KM; Müller-Tidow C; Mechtersheimer G; Goeppert B; Stenzinger A; Weinhold N; Goldschmidt H; Weisel K; Raab MS
Blood; 2023 Apr; 141(14):1685-1690. PubMed ID: 36608320
[TBL] [Abstract][Full Text] [Related]
11.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
12. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
13. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G
J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
16. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
19. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
20. BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ; Chen Z; Rosen N; Solit DB
Nat Rev Clin Oncol; 2024 Mar; 21(3):224-247. PubMed ID: 38278874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
